(MKKGY) –
-
MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour
-
MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing
-
Merck KGaA (MRK:GR) (MKKGY) PT Raised to EUR192 at Stifel
-
MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea
-
Merck KGaA (MRK:GR) (MKKGY) PT Raised to EUR210 at Citi
-
EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
-
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
-
Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
-
MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis
-
EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District
-
MilliporeSigma Launches ChemisTwin™, First Ever Digital Reference Material Platform for Analytical Testing
-
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
-
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
-
Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS
-
EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation
-
EMD Serono Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support Caregivers
-
EMD Serono Launches New Collaboration with United Nations’ Global Initiative on Ageing to Support Caregivers
-
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
-
Merck KGaA (MRK:GR) (MKKGY) PT Lowered to EUR185 at HSBC
-
Data Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement
-
Merck KGaA (MRK:GR) (MKKGY) PT Lowered to EUR200 at Barclays
-
MilliporeSigma Invests $25 Million to Expand Cell Culture Media Production in Kansas
-
Athinia™ expands partnerships to include Tokyo Electron for real-time collaborative analytics of semiconductor fab equipment performance
-
Merck KGaA (MRK:GR) (MKKGY) PT Lowered to EUR220 at JPMorgan
-
BofA Securities Reiterates Buy Rating on Merck KGaA (MRK:GR) (MKKGY)
-
MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech Grant
-
EMD Serono Highlights Commitment to Improving Cancer Outcomes at ASCO 2023
-
Merck KGaA (MRK:GR) (MKKGY) PT Lowered to EUR225 at JPMorgan
-
Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
-
EMD Serono Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS
-
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma
-
MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems Acquisition
-
MilliporeSigma Invests $ 286 Million in U.S. Drug Safety Testing Capacity
-
EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment
-
EMD Serono Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care
-
Merck KGaA (MRK:GR) (MKKGY) PT Lowered to EUR200 at Morgan Stanley
-
MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO Services
-
MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, France
-
Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care
-
EMD Serono to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
-
MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
-
Merck KGaA (MRK:GR) (MKKGY) PT Raised to EUR125 at Societe Generale
-
MilliporeSigma Breaks Ground on Company's First Lateral Flow Membrane Production Facility in the United States
-
Micron to Select Athinia™ for Pioneering Data Collaboration
-
MilliporeSigma Opens US$ 65 Million CDMO Facility to Address Demand for Critical Cancer Therapies
-
EMD Serono Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways
-
Merck KGaA (MRK:GR) (MKKGY) PT Lowered to EUR198 at Goldman Sachs
-
EMD Serono to Present Latest Research From Oncology Portfolio at ASCO 2022
-
MilliporeSigma Announces the Expansion of Hands-On Science Education Program with Kick-off of Global Curiosity Cube® Mobile Lab
-
Merck KGaA (MRK:GR) (MKKGY) PT Lowered to EUR186 at Societe Generale
Back to MKKGY Stock Lookup
